Stocks to Watch: Medicenna Therapeutics Corp. (TSX:MDNA) Up +28.65%

At close of market on Friday, Medicenna Therapeutics Corp. (TSX:MDNA) stock finished trading at +28.65%, bringing the stock price to $2.20 on the Toronto Stock Exchange. The stock price saw a low of $2.05 and a high of $2.38.

The company’s stock was traded 415 times with a total of 193,809 shares traded.

Medicenna Therapeutics Corp. has a market cap of $62.87 million, with 28.58 million shares in issue.

Medicenna Therapeutics Corp is a Canada based immuno-oncology company. Its principal business activity is the development and commercialization of Empowered Cytokines and Superkines for the treatment of cancer. The company is engaged in developing Interleukin-4 Empowered Cytokines (IL4-ECs) that specifically target the Interleukin-4 Receptor (IL4R) which is over-expressed by 20 different cancers, cancer stem cells and immunosuppressive cells of the tumor microenvironment. The IL4-ECs have the potential to purge the tumor and un-blind the immune system to cancer thereby altering the treatment paradigm for a large majority of cancer patients.

error: Content is protected !!